Virus-host interaction mechanisms in interferon therapy for hepatitis B virus infection: recent advances

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis B virus (HBV) infection leads to severe liver diseases and significant economic burden.
• Current treatments like nucleos(t)ide analogs (NAs) and interferon-α (IFN-α) have limited efficacy and cannot eliminate covalently closed circular DNA (cccDNA).
• Hepatitis B surface antigen (HBsAg) eradication and clinical cure remain challenging with existing therapies.

Purpose of the Study:

• To comprehensively review host-related factors influencing interferon therapy for chronic hepatitis B (CHB).
• To highlight the importance of understanding and managing these host factors for improved treatment outcomes.
• To explore strategies for enhancing the clinical cure rate of hepatitis B.

Main Methods:

• Literature review of studies on host factors affecting interferon therapy for CHB.
• Analysis of existing data on the efficacy and limitations of current CHB treatments.
• Synthesis of information on host- and viral-related factors impacting IFN treatment outcomes.

Main Results:

• Host factors significantly influence the efficacy of interferon therapy in CHB patients.
• Suboptimal therapeutic outcomes and complications are associated with current IFN-based treatments.
• Monotherapy with novel antiviral drugs is currently insufficient for achieving a clinical cure.

Conclusions:

• Managing host-related factors is crucial for optimizing interferon treatment efficacy in CHB.
• Addressing these factors can minimize adverse reactions and improve patient tolerance.
• Enhanced understanding and management of host factors hold the potential to increase the clinical cure rate for hepatitis B.